CA-PULSESG
20.10.2021 15:02:13 CEST | Business Wire | Press release
pulsESG™ today announced the launch of its enterprise environmental, social, and governance (ESG) software as a service (SaaS) platform backed by $8.5 million in seed funding from leading impact-driven investors and led by two Silicon Valley enterprise software veterans. The platform distinguishes itself in the marketplace through features such as model-driven architecture and full integration with both internal sources of data and external investor-facing systems, empowering companies to track and derive insights for ESG compliance and improvement based on stakeholder requirements. The company emerged from stealth mode today and the product is expected to be made generally available in Q1 2022.
Led by tech veterans and co-founders Murat Sönmez and Inderjeet Singh, the pulsESG™ platform is designed to take a different approach to ESG analysis than what currently exists in the marketplace by providing comprehensive, auditable, and accurate deep analytics that can be integrated with both the source and destination ESG systems of customers. This new level of information empowers enterprises to make more informed ESG decisions using a platform that also provides end-users the flexibility to modify it based on changes in the ESG regulatory landscape and according to their stakeholder needs.
“Amidst changing impact benchmarks at national and global levels, accurate and reliable ESG analysis is moving from ‘nice-to-have’ to ‘must-have’ for enterprises worldwide, so we sought to develop a platform to help customers navigate this fluid landscape,” explained Co-founder, President, and CTO Inderjeet Singh. “The pulsESG™ platform was designed to raise the bar on quality and timeliness, allowing customers to respond to changes in the ESG models themselves, not just data points within current data models.”
“Simply put, pulsESG™ offers an integrated, comprehensive, and flexible SaaS platform for enterprises to define, capture, analyze, derive insight, and improve their ESG footprint,” added Murat Sönmez, Co-founder and CEO.
While private equity firms, their investors, and other stakeholders increasingly take ESG impacts and risk into account, the measurement tools and benchmarks for each continue to evolve—both across sectors and jurisdictions. Sönmez and Singh saw the opportunity to leverage their experience with SaaS platforms, integration, business processes, analytics, and master data management to create a system to help enterprises navigate and respond to this inherent fluidity in ESG analysis. The result of their vision is the pulsESG™ platform.
Sönmez and Singh have found early backing from leading investors in the impact-driven investment space, including FINTOP Capital, Aligned Climate Capital, SOMPO Holdings (Japan), Builders VC, eLab Ventures, and individual investors including Alberto Cribiore and André Borschberg.
Prior to co-founding pulsESG™, Murat Sönmez was a member of the founding team at TIBCO Software and led it past the billion-dollar revenue mark as the head of its customer facing operations. Sönmez later joined the Managing Board of the World Economic Forum in Switzerland, leading its global business community engagement efforts, and subsequently established and led its global technology policy network out of San Francisco.
pulsESG™ Co-founder Inderjeet Singh was most recently responsible for Oracle’s middleware and cloud platform and previously for TIBCO’s infrastructure products. Inderjeet joined TIBCO Software through the acquisition of Velosel—a leading master data management platform—where he was part of the founding team and led all product functions.
Investor Statements
“ESG reporting is quickly becoming standard practice for companies and investors worldwide. As an investor that cares deeply about ESG, we are excited about pulsESG’s ability to ensure that analysis and reporting is more real, reliable, and reportable."
— Peter W. Davidson, CEO, Aligned Climate Capital
"As one of the world’s largest economies, Japan faces pressure from an aging society with social impact and other ESG considerations steering business decisions more than ever. SOMPO has been working to address these issues in innovative ways and utilizing digital technologies to accurately measure our impact, so are excited to have found a partner in pulsESG—an integrated and comprehensive platform with the potential to accelerate SOMPO’s impact for society.”
— Kengo Sakurada, Group CEO, Director, President and Representative Executive Officer, SOMPO Holdings, Inc.
“In a crowded field of ESG platforms, Murat and Inderjeet stand apart with the completeness of their vision, passion for impact, and unparalleled combined experience in successfully scaling startups, developing mission-driven software platforms, and executing strategic engagement with top level leadership in organizations worldwide. We are pleased to lead the investment and look forward to an impactful journey together.”
— Rick Kushel, Co-founder and General Partner of FINTOP Capital
About pulsESG™
Founded in 2021, pulsESG, Inc. is a public benefit corporation dedicated to empowering purpose-driven enterprises to manage and improve their ESG footprint with an integrated and comprehensive SaaS platform built for compliance tracking and insight.
For more information: www.pulsESG.com
LinkedIn: www.linkedin.com/company/pulsESG
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom